Aduro is developing novel therapies that induce highly targeted, potent and sustained immune responses against a variety of cancers. This drug development effort is driven by the company’s core LADD platform (Live, Attenuated, Double-Deleted Listeria mononcytogenes), and our various product programs use LADD-based agents both as monotherapies and in combination with existing conventional and newly emerging cancer therapies, including GVAX, chemotherapy, radiotherapy and checkpoint inhibitors.
The company is also in the early stages of developing a complementary technology platform based on CDNs (cyclic dinucleotides). These small molecules adjuvants help stimulate the important STING pathway inside immune cells. Aduro has developed proprietary modifications of these naturally occurring compounds to enhance their cancer-fighting characteristics.